Derived From Bacteria Patents (Class 435/220)
-
Publication number: 20110262998Abstract: A process for preparing an inclusion body-forming protein is provided.Type: ApplicationFiled: October 21, 2009Publication date: October 27, 2011Applicants: TEIJIN PHARMA LIMITED, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Hiroshi Nakatake, Akihiro Meta, Kiyotaka Suenaga, Masaki Hirashima, Hiroaki Maeda
-
Publication number: 20110256094Abstract: Disclosed are isolated Chlamydia trachomatis proteins, methods of fusion protein and associated antibody production, and methods of using isolated proteins and antibodies in diagnosis and detection. Also disclosed are compositions comprising isolated proteins, wherein the compositions can further comprising pharmaceutically acceptable carriers, an adjuvant and/or an immunostimulant, and methods using the pharmaceutical compositions for treating or preventing an infection by Chlamydia in a subject. The compositions may also comprise a protein or immunogenic fragment of a pathogenic organism other than Chlamydia trachomatis.Type: ApplicationFiled: October 9, 2009Publication date: October 20, 2011Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEMInventor: Guangming Zhong
-
Compositions and methods for the prevention and removal of biofilms on inert and biological surfaces
Patent number: 8038990Abstract: Organisms, compositions, and methods for at least partially reducing the formation of a biofilm and/or at least partially removing a biofilm are provided. The organisms, compositions, and methods may be used on biotic and abiotic surfaces.Type: GrantFiled: June 1, 2006Date of Patent: October 18, 2011Assignee: The Ohio State UniversityInventors: Hua Wang, Hongliang Luo -
Publication number: 20110252509Abstract: This invention relates generally to a method for producing a transgenic cell with increased gamma-aminobutyric acid (GABA) content as compared to a corresponding non-transformed wild type cell.Type: ApplicationFiled: October 23, 2009Publication date: October 13, 2011Applicant: BASF Plant Sceince GmbHInventors: Janneke Hendriks, Hardy Schön, Oliver Thimm, Volker Haake, Gunnar Plesch, Piotr Puzio, Astrid Blau, Michael Manfred Herold, Birgit Wendel, Beate Kamlage, Florian Schauwecker
-
Publication number: 20110243909Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: April 12, 2011Publication date: October 6, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110243919Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: April 12, 2011Publication date: October 6, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110243920Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: April 12, 2011Publication date: October 6, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110243908Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: April 12, 2011Publication date: October 6, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110217287Abstract: A pharmaceutical preparation comprising one of the botulinum neurotoxins from Clostridium botulinum of types A, B, C, D, E, F or G or a mixture of two or more of these neurotoxins, wherein the neurotoxin or the mixture of neurotoxins is free of the complexing proteins which naturally form the botulinum neurotoxin complexes together with the neurotoxins.Type: ApplicationFiled: May 11, 2011Publication date: September 8, 2011Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Hans Bigalke, Jürgen Frevert
-
Patent number: 8008059Abstract: A method of detection of cells, microorganisms, or molecules by the use of various combinations of fluorogens and a chromogens which yield fluorophores and chromophores when cleaved by specific enzymes and which can be viewed by UV and visible light. Included is the method of application of a family of compounds producing both insoluble fluorophores and chromophores identified as dual enzyme substrates.Type: GrantFiled: March 16, 2007Date of Patent: August 30, 2011Assignee: Micrology Laboratories, LLCInventors: Geoffrey N. Roth, Jonathan N. Roth
-
Publication number: 20110189162Abstract: The present specification discloses modified Clostridial toxins, compositions comprising an integrated protease cleavage site-binding domain, polynucleotide molecules encoding such modified Clostridial toxins and compositions comprising di-chain forms of such modified Clostridial toxins.Type: ApplicationFiled: December 16, 2010Publication date: August 4, 2011Applicant: ALLERGAN, INC.Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
-
Publication number: 20110189153Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: April 12, 2011Publication date: August 4, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110177056Abstract: The present invention relates to fusion proteins comprising a non-cytotoxic protease and a EGF mutein ligand. The EGF mutein provides improved EGF receptor activation for the claimed fusion proteins. Also provided is the use of said polypeptides as therapeutics for suppressing mucus hypersecretion, inflammation, endocrine neoplasia and/or neuroendocrine disorders, neuroendocrine tumours, for suppressing cancers such as colorectal cancer, prostate cancer, breast cancer, and lung cancer.Type: ApplicationFiled: August 19, 2009Publication date: July 21, 2011Applicant: SYNTAXIN LIMITEDInventors: Aimee Cossins, Ian Birch-Machin, Patrick Stancombe
-
Patent number: 7982003Abstract: The invention concerns a nucleic acid encoding a recombinant bifunctional fusion peptidoglycan hydrolase protein formed from a nucleic acid encoding a peptidoglycan hydrolase module and a nucleic acid encoding a second peptidoglycan hydrolase module. The fusion, dual (or multiples thereof) peptidoglycan hydrolase modules can be used to treat disease caused by the bacteria for which the individual modules of the fusion protein are specific.Type: GrantFiled: July 6, 2009Date of Patent: July 19, 2011Assignee: The United States of America as represented by the Secretary of AgricultureInventor: David M. Donovan
-
Publication number: 20110165619Abstract: Proteins having a cofactor can be secreted in an improved manner in a microorganism belonging to the genus Streptomyces provided that the microorganism contains a nucleic acid sequence which is not naturally present in it and which comprises at least the following sequence sections: a) nucleic acid sequence coding for a protein containing a cofactor, and b) a nucleic acid sequence which is at least 20% identical to the sequence given in SEQ ID NO. 1, or at least 20% identical to the sequence given in SEQ ID NO. 3, or a nucleic acid sequence which is structurally homologous to at least one of these sequences, wherein the amino acid sequence encoded by nucleic acid sequence b) functionally cooperates with the amino acid sequence encoded by nucleic acid sequence a) so that at least the amino acid sequence encoded by nucleic acid sequence a) is secreted by the microorganism.Type: ApplicationFiled: November 29, 2010Publication date: July 7, 2011Inventors: JOHANNES BONGAERTS, STEFAN EVERS, KERSTIN FOH, KARL-HEINZ MAURER
-
Publication number: 20110158976Abstract: The pharmaceutical use of proteases related to a protease derived from Nocardiopsis sp. NRRL 18262 (SEQ ID NO: 1), optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: ApplicationFiled: May 24, 2005Publication date: June 30, 2011Applicant: NOVOZYMES A/SInventors: Allan Svendsen, Svend Kaasgaard, Kim Borch, Morten Fischer, Dan Pettersson, Peter Colin Gregory
-
Publication number: 20110159485Abstract: The present teachings relate to the extraction of nucleic acid from solid materials. Provided are useful compositions, methods and kits for obtaining nucleic acids from a solid biological sample or an adhesive material having a biological material adherent or embedded within the adhesive substrate. The extracted nucleic acid can be used in downstream applications such as genotyping, detection, quantification, and identification of the source of the biological material.Type: ApplicationFiled: September 14, 2010Publication date: June 30, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: James Stray, Jason Yingjie Liu, Maxim Brevnov, Jaiprakash Shewale, Allison Holt
-
Publication number: 20110158973Abstract: The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.Type: ApplicationFiled: December 16, 2010Publication date: June 30, 2011Applicant: SYNTAXIN LIMITEDInventors: Frederic MADEC, Phil LECANE, Philip MARKS, Keith FOSTER
-
Publication number: 20110158972Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: August 30, 2010Publication date: June 30, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110151053Abstract: Protease-like nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, protease-like fusion proteins, antigenic peptides, and anti-protease-like antibodies are encompassed. The invention also provides vectors containing a nucleic acid molecule of the invention and cells into which the vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.Type: ApplicationFiled: January 20, 2011Publication date: June 23, 2011Applicant: North Carolina State UniversityInventors: Todd R. Klaenhammer, Eric Altermann, W. Michael Russell
-
Patent number: 7956167Abstract: The present invention provides a method for purifying Clostridium histolyticum collagenase type I and type II proteins from a complex mixture by subsequently performing a precipitation with ammonium sulfate, hydrophobic interaction chromatography, cation exchange chromatography, and anion chromatography. Conditions are provided which lead to a stabilized, partially purified preparation even after the precipitation step. The method of the invention leads to a quick and efficient removal of other proteolytic activities. The preparations according to the invention provide exceptionally pure and intact collagenase type I and type II proteins which are enzymatically active. The invention also provides blends of the two isolated proteins. The invention further provides the use of the purified collagenase proteins or blends thereof for treating a tissue sample in vitro.Type: GrantFiled: May 29, 2009Date of Patent: June 7, 2011Assignee: Roche Diagnostics Operations, Inc.Inventors: Werner Hoelke, Hellmut Eckstein, Michaela Fischer, Antje Liehre, Bernhard Suppmann, Johann-Peter Thalhofer
-
Patent number: 7943337Abstract: There is provided a method for specifically determining a glycated ?-chain N-terminal of glycated hemoglobin using enzymes without a separation operation, and a determination reagent kit therefor. A protease that cleaves a glycated amino acid and/or a glycated peptide from a glycated ?-chain N-terminal without substantially cleaving a glycated amino acid or a glycated peptide from a glycated ?-chain N-terminal of glycated hemoglobin or a fragment thereof is screened. The method of specifically determining a glycated ?-chain N-terminal of glycated hemoglobin and the determination reagent kit are provided by using the protease obtained by the screening method. According to the present invention, a glycated ?-chain N-terminal of glycated hemoglobin can specifically be determined without a separation operation.Type: GrantFiled: July 21, 2009Date of Patent: May 17, 2011Assignees: Asahi Kasei Pharma Corporation, Ichibiki Co., Ltd.Inventors: Takeshi Matsuoka, Shinji Koga, Takuji Kouzuma
-
Publication number: 20110097440Abstract: The present invention relates to a method for the improvement of the short bite and texture parameters of bakery products by adding thereto at least one intermediate thermostable or thermostable serine or metallo-protease.Type: ApplicationFiled: May 14, 2009Publication date: April 28, 2011Applicant: PURATOS N.V.Inventors: Bruno Van Winckel, Fabienne Verte
-
Publication number: 20110097445Abstract: The invention relates to a novel 3D structure encoding a Nocardiopsis protease, as well as to variants of parent protease homologous to Nocardiopsis proteases, preferably of improved thermostability and/or with an amended temperature activity profile. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of generating and preparing protease variants of amended properties.Type: ApplicationFiled: January 5, 2011Publication date: April 28, 2011Applicant: Novozymes A/SInventors: Leonardo De Maria, Carsten Andersen, Lars Lehmann Hylling Christensen, Søren Flensted Lassen, Peter Rahbek Østergaard
-
Publication number: 20110070622Abstract: The present invention provides a method for purifying Clostridium histolyticum collagenase type I and type II proteins from a complex mixture by subsequently performing a precipitation with ammonium sulfate, hydrophobic interaction chromatography, cation exchange chromatography, and anion chromatography. Conditions are provided which lead to a stabilized, partially purified preparation even after the precipitation step. The method of the invention leads to a quick and efficient removal of other proteolytic activities. The preparations according to the invention provide exceptionally pure and intact collagenase type I and type II proteins which are enzymatically active. The invention also provides blends of the two isolated proteins. The invention further provides the use of the purified collagenase proteins or blends thereof for treating a tissue sample in vitro.Type: ApplicationFiled: May 29, 2009Publication date: March 24, 2011Inventors: Werner Hoelke, Hellmut Eckstein, Michaela Fischer, Antje Liehre, Bernhard Suppmann, Johann-Peter Thalhofer
-
Patent number: 7906310Abstract: The invention relates to a novel class of serine proteases of peptidase family S2A or S1E that are stable in the presence of copper (Cu2+) and/or inhibited by copper only to a limited extent. Structural features of potential relevance for this effect are also disclosed. This class of proteases includes proteases derived from Brachysporiella gayana, Nocardiopsis dassonvillei subsp. dassonvillei, Nocardiopsis prasina, and Nocardiopsis alba, but excludes the known proteases derived from Metarhizium anisopliae and Nocardiopsis sp. NRRL 18262. The invention also relates to DNA encoding such proteases, the expression thereof in a host cell, including animal and plant cells, as well as to the use thereof, e.g., in animal feed and in detergents. In particular, the invention relates to animal feed and animal feed additives, such as premix, incorporating these proteases together with 1-500 ppm Cu (in-feed-concentration).Type: GrantFiled: May 15, 2009Date of Patent: March 15, 2011Assignee: Novozymes A/SInventors: Peter Rahbek Oestergaard, Leonardo De Maria
-
Publication number: 20110045570Abstract: The invention aims to provide a novel alkaline protease having peculiar properties such as high alkali activity, resistance to surfactants and calcium-dependent thermostability and exhibiting excellent performance in highly alkaline detergents, and a gene coding for the amino acid sequence thereof. There is provided an alkaline protease with such properties that an active pH range is from 5 to 13, an optimum pH is approximately 12.6, an optimum temperature is 70° C., no activity drop by heating is observed up to 65° C. at pH 10 and the optimum temperature and the thermostability are not affected by Ca2+ ions. Specifically, there is provided, for example, an alkaline protease having an amino acid sequence constituting a mature enzyme as represented by SEQ ID NO: 3 or an amino acid sequence resulting from deletion, substitution, situs inversus arrangement, addition or insertion of a part of amino acids thereof, or derived from Alkaliphillus transvaalensis.Type: ApplicationFiled: November 16, 2005Publication date: February 24, 2011Applicant: Japan Agency for Marine-Earth Science and Tech.Inventors: Jie Lu, Zhijun Li, Si Hung Vo, Yuji Hatada, Ken Takai, Susumu Ito, Koki Horikoshi
-
Patent number: 7892808Abstract: The invention relates to a novel 3D structure determined for a Nocardiopsis protease, as well as to variants of parent protease homologous to Nocardiopsis proteases, preferably of improved thermostability and/or with an altered temperature activity profile. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention further relates to methods of generating and preparing protease variants having different properties.Type: GrantFiled: October 8, 2004Date of Patent: February 22, 2011Assignee: Norozymes A/SInventors: Leonardo De Maria, Carsten Andersen, Lars Lehmann Hylling Christensen, Soren Flensted Lassen, Peter Rahbek Ostergaard
-
Publication number: 20100322917Abstract: The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.Type: ApplicationFiled: December 28, 2006Publication date: December 23, 2010Applicant: INSECT BIOTECH CO., LTD.Inventors: Ho-Yong Park, Kwang-Hee Son, Dong-Ha Shin, Kyu-Shik Jeong
-
Patent number: 7846231Abstract: There are provided a method of treating organic waste, which is excellent in the smooth temperature elevation in the early stage of the treatment and satisfactory in temperature-maintenance in a high temperature range, and by which the stable treatment of organic waste is achieved and the evaporation of moisture is promoted, thereby a stable effect of treating organic waste and an increased treatment scale being achieved; an agent for treating organic waste; and microorganisms to be used therein. The method is characterized by the use of a mesophilic bacterium showing its activity at 15 to 50° C. and a thermophilic bacterium showing its activity at 50 to 70° C. in the organic waste. As the mesophilic bacteria, bacteria which have an exothermic action and form spores under a temperature of 50° C. or higher are preferable and Bacillus subtilis is more preferable. Among these bacteria, a C-3102 strain (FERM BP-1096) is especially preferable.Type: GrantFiled: January 29, 2004Date of Patent: December 7, 2010Assignee: Calpis Co., Ltd.Inventors: Hiroshi Miyazaki, Kiyoshi Maruta, Tomohiro Hamaoka
-
Publication number: 20100261252Abstract: The present disclosure relates in general to methods for recombinantly producing soluble, active IgA proteases (e.g., IgA1 proteases) in host cells (e.g., bacterial cells), and methods for using IgA proteases (e.g., IgA1 proteases) produced by the methods to treat IgA deposition disorders (e.g., IgA nephropathy).Type: ApplicationFiled: April 9, 2010Publication date: October 14, 2010Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Shinong Long, Michel C. Vellard
-
Patent number: 7794966Abstract: The present invention aims to enable highly reliable measurement of a glycated amine. A fructosyl amino acid oxidase (FAOD) is added to a sample to remove a non-analyte glycated amine that is present in the sample and different from an analyte glycated amine. Thereafter, a protease is added to the sample to degrade the analyte glycated amine, and the degradation product of the analyte glycated amine reacts with the FAOD that has already been added to the sample. By measuring this redox reaction, the amount of the analyte glycated amine can be measured.Type: GrantFiled: December 10, 2004Date of Patent: September 14, 2010Assignee: Arkray, Inc.Inventor: Kaoru Hirai
-
Publication number: 20100184137Abstract: The present invention provides methods of altering the production of desired polypeptides in a host cell. In particular, the present invention provides polynucleotides encoding truncated SecG proteins capable of facilitating the secretion of desired proteases by a bacterial host cell, such as Bacillus species, as well as expression vectors and a host cell containing the polynucleotides.Type: ApplicationFiled: May 12, 2008Publication date: July 22, 2010Inventors: Anita Van Kimmenade, Carol Fioresi, Caroline Peres, Eugenio Ferrari
-
Publication number: 20100159564Abstract: The identification of the most sensitive sites of Clostridium histolyticum collagenase Class 1 to proteolysis by proteases present during the fermentation and purification of the enzyme is described. Culture supernatant obtained after fermentation of C. histolyticum is used as the starting material for further purification of the enzyme. Native collagenase Class 1 and its proteolytic fragments are partially purified by a combination of hydrophobic interaction and strong anion exchange chromatographies. The pools containing enriched levels of the proteolytic fragments are further purified by high performance anion exchange chromatography. These polypeptides are then characterized by Q-TOF mass spectroscopy. A total of three sensitive bonds are identified along with substitution and deletion strategies that will result in resistance of the enzyme to proteolytic degradation.Type: ApplicationFiled: December 1, 2008Publication date: June 24, 2010Inventors: Francis E. Dwulet, Andrew G. Breite, Robert C. McCarthy
-
Patent number: 7741438Abstract: The present invention concerns the methods and compositions involving endopeptidase enzymes, especially PepO2 and PepO3 from L. helveticus, and their use in reducing bitterness by cleaving bitter peptides. In particular embodiments of the invention, these methods and compositions apply to the cheesemaking process. The invention also concerns the use of PepO2 and/or PepO3 polypeptides in the treatment or prevention of celiac sprue or as a food additive.Type: GrantFiled: June 21, 2004Date of Patent: June 22, 2010Assignees: Wisconsin Alumni Research Foundation, Utah State UniversityInventors: James L. Steele, Jeffrey R. Broadbent, Vidya R. Sridhar
-
Publication number: 20100092451Abstract: A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy.Type: ApplicationFiled: March 14, 2008Publication date: April 15, 2010Inventors: Jonathan David Gass, Chaitan Khosla, Michael Bethune, Matthew John Siegel
-
Patent number: 7662935Abstract: The invention provides novel methionine aminopeptidase enzymes and their use.Type: GrantFiled: May 26, 2009Date of Patent: February 16, 2010Assignee: Novo Nordisk A/SInventors: Inga Sig Nielsen Nørby, Lars Fogh Iversen
-
Patent number: 7642069Abstract: An improved process for the production of streptokinase using a genetically engineered strain of Escherichia coli which overproduces streptokinase intracellularly and more particularly, the overall process disclosed herein, concerns with an improvement in the fermentative production of streptokinase using an optimized growth medium mainly comprised of simple salts and trace-elements; thus, in principal, the present process constitutes an improved and more economical means for the production of streptokinase which may be useful in thrombolytic therapy.Type: GrantFiled: December 9, 2005Date of Patent: January 5, 2010Assignee: Council of Scientific & Industrial ResearchInventors: Vinay Venkatrao Vyas, Govindan Rajamohan, Ramandeep, Kanak Lata Dikshit
-
Publication number: 20090304754Abstract: Glutenase proteins, such as prolyl endopeptidases, are stabilized by covalent PEG modification.Type: ApplicationFiled: October 11, 2006Publication date: December 10, 2009Inventor: Srebrenka Robic
-
Publication number: 20090291457Abstract: The present invention provides a method for designing a re-targeted toxin conjugate for use in treating a medical condition or disease. Also provided, is the use of said conjugates in the manufacture of a medicament for treating medical conditions or diseases. The conjugates include a Targeting Moiety, which directs the conjugate to a desired target cell, and are characterised by a Targeting Moiety that increases exocytic fusion in the target cell. The present invention also provides methods for identifying agonists suitable for use as Targeting Moieties, and methods for preparing conjugates comprising said Targeting Moieties.Type: ApplicationFiled: August 3, 2009Publication date: November 26, 2009Applicant: SYNTAXIN LIMITED, SalisburyInventors: Keith Foster, John Chaddock, Charles Penn
-
Publication number: 20090280555Abstract: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.Type: ApplicationFiled: October 29, 2007Publication date: November 12, 2009Inventors: Felix Hausch, Gary Gray, Lu Shan, Chaitan Khosla
-
Publication number: 20090238922Abstract: The invention relates to a novel class of serine proteases of peptidase family S2A or S1E that are stable in the presence of copper (Cu2+) and/or inhibited by copper only to a limited extent. Structural features of potential relevance for this effect are also disclosed. This class of proteases includes proteases derived from Brachysporiella gayana, Nocardiopsis dassonvillei subsp. dassonvillei, Nocardiopsis prasina, and Nocardiopsis alba, but excludes the known proteases derived from Metarhizium anisopliae and Nocardiopsis sp. NRRL 18262. The invention also relates to DNA encoding such proteases, the expression thereof in a host cell, including animal and plant cells, as well as to the use thereof, e.g., in animal feed and in detergents. In particular, the invention relates to animal feed and animal feed additives, such as premix, incorporating these proteases together with 1-500 ppm Cu (in-feed-concentration).Type: ApplicationFiled: May 15, 2009Publication date: September 24, 2009Applicant: Novozymes A/SInventors: Peter Rahbek Oestergaard, Leonardo De Maria
-
Patent number: 7588910Abstract: There is provided a method for specifically determining a glycated ?-chain N-terminal of glycated hemoglobin using enzymes without a separation operation, and a determination reagent kit therefor. A protease that cleaves a glycated amino acid and/or a glycated peptide from a glycated ?-chain N-terminal without substantially cleaving a glycated amino acid or a glycated peptide from a glycated ?-chain N-terminal of glycated hemoglobin or a fragment thereof is screened. The method of specifically determining a glycated ?-chain N-terminal of glycated hemoglobin and the determination reagent kit are provided by using the protease obtained by the screening method. According to the present invention, a glycated ?-chain N-terminal of glycated hemoglobin can specifically be determined without a separation operation.Type: GrantFiled: May 21, 2004Date of Patent: September 15, 2009Assignees: Asahi Kasei Pharma Corporation, Ichibiki Co., Ltd.Inventors: Takeshi Matsuoka, Shinji Koga, Takuji Kouzuma, Issei Yoshioka, Atsuhisa Nishimura, Homare Itou, Toshihiko Kumazawa, Takashi Kuroyanagi
-
Publication number: 20090181007Abstract: A composition for in vitro use as a culture medium or in vivo use as a pharmaceutical composition or a medical device, capable of accelerating the differentiation of stem cells into cells with a chondrocytic phenotype and of restoring the original trophism of chondrocytes, is described. The composition comprises, in combination, at least one proteolytic enzyme, at least one growth factor and at least one from a sugar, an amino acid, a vitamin factor, a vitamin, a nucleotide and a nucleoside, in a physiologically acceptable carrier or diluent. A method of differentiating stem cells in cells having a chondrocytic phenotype, the cells obtained by the method and their uses, for example in human or animal cell therapy, for example by CBMP (Cellular Based Medicinal products) are also described.Type: ApplicationFiled: April 12, 2007Publication date: July 16, 2009Inventors: Luisa Gennero, Antonio Ponzetto, Enrico De Vivo, Luciano Contu, Emanuella Morra, Chiara Cesano, Giovanni Cavallo, Giuseppe Cicero, Gian Piero Pescarmona, Tetyana Denysenko, Maria Augusta Roos, Maurizio Sara
-
Publication number: 20090111161Abstract: Certain aspects of this disclosure relate to an isolated protease, and cleaning compositions containing the same. In some embodiments, the protease may comprise an amino acid sequence that is at least 80% identical to the wild type Streptomyces 1AG3 protease. Isolated nucleic acid encoding the subject protease, recombinant nucleic acid containing the same and host cells containing the recombinant nucleic acid are also provided.Type: ApplicationFiled: October 30, 2007Publication date: April 30, 2009Inventors: Brian E. Jones, Marc Kolkman, Chris Leeflang
-
Patent number: 7524655Abstract: This invention provides nucleic acid and amino acid sequences of fucosyltransferases from Helicobactor pylori. The invention also provides methods to use the fucosyltransferases to synthesize oligosaccharides, glycoproteins, and glycolipids.Type: GrantFiled: December 6, 2005Date of Patent: April 28, 2009Assignees: Neose Technologies, Inc., Governors of the University of AlbertaInventors: Karl F. Johnson, Daniel James Bezila, Diane E. Taylor, Joanne Simala-Grant, David Rasko
-
Publication number: 20090092707Abstract: Isolated polypeptides are disclosed selected from the group consisting of: (a) polypeptides comprising an amino acid sequence which has at least 90% identity with a sequence of a mature polypeptide comprised in the group of SEQ ID NO: 26 to SEQ ID NO:50; (b) polypeptides which are encoded a nucleotide sequence which hybridize under high stringency conditions with a polynucleotide probe selected from the group consisting of (i) the complementary strand to a nucleotide sequence selected from the group of regions of SEQ ID NO: 1 to SEQ ID NO: 25 encoding a mature polypeptide.Type: ApplicationFiled: August 4, 2008Publication date: April 9, 2009Applicant: Novozymes A/SInventors: Reinhard Wilting, Soren Flensted Lassen, Peter Rahbek Ostergaard
-
Patent number: 7498148Abstract: The invention provides methods for making peptides from a polypeptide containing at least one copy of the peptide using clostripain to excise the peptide from the polypeptide. The methods enable the use of a single, highly efficient enzymatic cleavage to produce any desired peptide sequence.Type: GrantFiled: November 21, 2007Date of Patent: March 3, 2009Assignee: Restoragen, Inc.Inventors: Fred W. Wagner, Peng Luan, Yuannan Xia, Daniel Strydom, Edwin H. Merrifield, Mary J. Bossard, Barton Holmquist, Jin Seog Seo
-
Patent number: RE41328Abstract: A purified heparinase I, II and III free of lyase activity and each having a molecular weight of 42,800 84,100, 70,800, respectively, are produced by culturing Flavobacterium heparinum. The kinetic properties of the heparinases have been determined as well as the conditions to optimize their activity and stability.Type: GrantFiled: August 27, 2008Date of Patent: May 11, 2010Assignees: Massachusetts Institute of Technology, University of Iowa Research FoundationInventors: Ramnath Sasisekharan, Charles L. Cooney, Robert S. Langer, Daniel L. Lohse, Robert J. Linhardt
-
Purification, composition and specificity of Heparinase I, II, and III from Flavobacterium heparinum
Patent number: RE41461Abstract: A single, reproducible scheme to simultaneously purify all three of the heparin lyases from F. heparinum to apparent homogeneity is disclosed herein. The kinetic properties of the heparin lyases have been determined as well as the conditions to optimize their activity and stability. Mono-clonal antibodies to the three heparinases are also described and are useful for detection, isolation and characterization of the heparinases.Type: GrantFiled: August 27, 2008Date of Patent: July 27, 2010Assignees: Massachusetts Institute of Technology, University of Iowa Research FoundationInventors: Daniel L. Lohse, Robert J. Linhardt, Ramnath Sasisekharan, Charles L. Cooney, Robert S. Langer